What Caused The Opening Gap In Dova?

Clinical-stage pharmaceutical company Dova (NYSE: DOVA) today had a large opening gap of 25.68%.

Photo taken from the Opening Gap Signals tool inside Benzinga Pro.

Why Is It Moving?

Dova shares are trading higher after the company reported FDA approval of its supplemental New Drug Application for DOPTELET, expanding the use to include treatment of thrombocytopenia in adults with ITP.

Photo taken from the ‘Why Is It Moving?’ Details tool inside Benzinga Pro.

For live updates on DOVA log in or try Benzinga Pro today.